Abstract:Objective:In this study, we analyzed the efficacy and tolerability of mycophenolate mofetil and three other immunosuppressants in Graves’ ophthalmopathy (GO) patients. Methods:Fifty four untreated GO patients were enrolled in this study. The diagnosis of GO was based on the presence of the typical clinical features and excluding of the possibility of cranial/orbital diseases, and the severity of ophthalmopathy was at least equal to or more severe than Class 2 in NO SPECS classification. Those who could afford were randomly assigned to receive either mycophenolate mofetil (MMF, n =12, 16～18 mg per kilogram per day) or cyclosporin A (CsA, n =11, 5～6 mg per kilogram of body weight per day) therapy. The others were randomly assigned to be given either prednisone ( n =16, finished in 13 case, 40 mg per day for 4 weeks, 20 mg for 4 weeks, and 10 mg for 4 weeks) or tripterygium multi glycosides (T Ⅱ , n =15, 30～60 mg per day). The disease severity and therapeutic response were quantitatively assessed according to the Ophthalmopathy Index Scoring System from Given wilson (1989) with sensibly modified. The improvement or progression of ophthalmopathy was defined if the variation, either increase or decrease of the score, reached 3 or more in the ophthalmopathy index. If this did not occur, a lack of response was indicated. In patients who had hyperthyroidism, antithyroid drugs were also administered.Results:After 12 week therapy, 7 (54 percent) of the 13 treated with prednisone improved, the remaining 6 (46 percent) lacked response. In T Ⅱ group, 10 (67 percent) of 15 responded to the therapy, 5 (33 percent) had no change. There was no significant difference in clinical response between the above 2 groups ( P 0.05). Five CsA treated and 11 MMF treated patients responded to therapy (45 percent vs 92 percent; P 0.05) . It seems that MMF is more effective than CsA in the treatment of GO although a significant decrease ( P 0.01) in the mean score of the CsA group has also been shown at the end of the course. None of all the 51 patients in the 4 groups had worsening of ophthalmopathy. Among 16 patients in prednisone group, 3 (19 percent) gained body weight by more than 5 percent, 2 (13 percent) developed impaired glucose tolerance (IGT). These two patients and one of the three weight gaining patients ceased the therapy. Impermanent menopause happened in 1 (11 percent) of the females in T Ⅱ group at the sixth month in sequel treatment after the course. Conclusion:MMF may be more effective than CsA in the treatment of Graves’ophthalmopathy. T Ⅱ may have a equal effectiveness and perhaps a better tolerability than prednisone in the immunotherapy of Graves’ ophthalmopathy.

Efficacy and Safety of Cyclophosphamide for the Treatment of Graves’ Ophthalmopathy: A Meta-Analysis

The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves’ Ophthalmopathy: A Systematic Review and Single-Arm Meta-Analysis

Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis

Corticosteroids for Graves' Ophthalmopathy: Systematic Review and Meta-Analysis.

Combined glucocorticoids and cyclophosphamide in the treatment of Graves' ophthalmopathy: a systematic review and meta-analysis

A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.

Clinical Efficacy of Combined Rituximab Treatment in a Woman with Severe Graves' Ophthalmopathy.

Retraction: Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.

Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves'ophthalmopathy: a systematic review and meta-analysis

Therapeutic Outcomes of Mycophenolate Mofetil and Three Other Immunosuppressants in Patients with Graves’ Ophthalmopathy

Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves’ Orbitopathy

Efficacy and Safety of Mycophenolate Mofetil in Patients with Active Moderate-To-Severe Graves' Orbitopathy

Immunosuppressive therapies in patients with Graves' ophthalmopathy]

Recent Advances in Graves Ophthalmopathy Medical Therapy: a Comprehensive Literature Review.

Analysis of the Impact of Ambulatory Care Based on Social Support on the Quality of Life of Patients with Graves' Ophthalmopathy

Efficacy Of Subantimicrobial Dose Doxycycline For Moderate-To-Severe And Active Graves' Orbitopathy

The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients

A randomized clinical trial of intravenous methylprednisolone with two protocols in patients with Graves' Orbitopathy.

Association Between Intravenous Pulse-Therapy with Immunosuppressant for Graves' Ophthalmopathy and Changes of Peripheral Blood T Cell Subgroup

A Retrospective Study of Clinical Features and Prognosis of Patients with Graves' Disease and Ophthalmopathy.

Methotrexate Plus Reduced or Full-Dose Glucocorticoids for the Treatment of Active, Moderate-to-severe Graves' Orbitopathy.